嗜睡症治疗市场－全球产业规模、份额、趋势、机会、预测：依治疗方法、产品、地区和竞争格局划分，2021-2031年

全球嗜睡症治疗市场预计将从 2025 年的 34.2 亿美元成长到 2031 年的 50.9 亿美元，复合年增长率为 6.85%。

这些疗法涉及药物干预，旨在治疗因大脑无法调节睡眠-觉醒週期而导致的慢性神经系统疾病，主要针对白天过度嗜睡、猝倒和夜间睡眠障碍等症状。该领域的发展主要得益于睡眠障碍在全球范围内日益普遍，以及诊断技术的进步，使得医疗专业人员能够早期发现疾病。此外，基于机制的治疗方法开发和支持孤儿药的法律规范为产业扩张奠定了坚实的基础，使其发展轨迹不受市场短期波动的影响。

儘管存在这些积极迹象，但市场仍面临与复杂诊断流程相关的重大障碍，这往往导致治疗启动时间大幅延迟。根据2023年睡眠研究协会的数据，发作性睡病影响着大约每10万人口中的37.7人。这项统计数据凸显了由于疾病的罕见性和漏诊率高，患者数量有限所带来的困境。再加上特效药物的高昂费用，这些因素都对市场的快速扩张构成了重大阻碍。

市场驱动因素

随着新疗法研发管线的拓展和新一代药物的核准，嗜睡症治疗市场格局正发生根本性的重塑。製药公司正从广泛缓解症状转向针对潜在病理学因素的标靶治疗，尤其关注Orexin讯号通路和组织胺调节。这种转变体现在缓释製剂日益增长的商业性价值上，缓释製剂显着减轻了患者的用药负担，而这些先进治疗方法的迅速普及也凸显了市场对依从性更佳治疗方法的强劲需求。例如，Abadel Pharmaceuticals在其2024年8月的财报中宣布，其新推出的治疗药物Lumryz第二季净销售额达到4,150万美元，显示临床疗效和给药便利性是推动销售的主要因素。

同时，优惠的报销方案和患者准入计划的推出，正成为有效将已确诊患者转化为接受治疗患者的关键驱动因素。生物製药公司认识到未治疗睡眠障碍的长期经济影响，正利用支持服务来确保药物的可持续可及性。根据Jazz Pharmaceuticals于2024年2月发布的2023年全年财报，第四季接受Xywav治疗的患者平均人数增至约12,300人。用户群的扩大凸显了透过改善病患准入所取得的商业性成功，该产品系列2023年的年度净销售额达到12.7亿美元，也直接支撑了整个产业的整体估值。

市场挑战

与发作性睡病相关的复杂诊断过程是全球治疗市场发展的主要障碍，人为地限制了目标患者群体。白天过度嗜睡等症状常被全科医生误诊为忧郁症、失眠或生活方式问题的征兆，而未被识别为特定的神经系统疾病。这种缺乏准确临床诊断的情况导致治疗路径支离破碎，患者往往在接受专业睡眠药物治疗前经历多年的无效治疗。因此，製药公司面临的市场范围显着缩小，有效的治疗方法无法惠及那些未被诊断或误诊的患者。

这种诊断缺口直接给依赖处方笺量来收回研发成本的药物研发者带来了高风险，并有效地限制了他们的收入潜力。患者识别效率低下导致市场规模远小于疾病的实际盛行率。根据嗜睡症网路对2025年的预测，约有50%的嗜睡症患者将无法确诊。这种严重的漏诊使得商业市场远远未达到其真正的潜力，直接阻碍了扩充性，并抑制了整个产业的扩张。

市场趋势

市场上的一项重大进展是选择性Orexin受体促效剂的出现。这使得治疗重点从缓解一般症状转向标靶化疾病的潜在病理生理机制。与非选择性调节中枢神经系统活动的传统兴奋剂不同，这些新型候选药物旨在直接刺激Orexin受体，从而解决导致睡眠-觉醒节律紊乱的特定神经肽缺乏问题。这种以机制为基础的治疗方法因其能够恢復自然觉醒状态而非仅仅掩盖困倦感，正迅速获得临床疗效。例如，武田製药公司于2024年6月报告称，其在研口服Orexin受体2促效剂TAK-861在安慰剂对照试验中，在觉醒维持测试（MWT）中显示出统计学意义上的显着改善（p < 0.001）。

同时，随着低滥用风险、未分类药物疗法的研发不断推进，以克服与管制药物相关的取得限制，竞争格局正在重塑。儘管目前的标准疗法通常由于监管规定而需要复杂的风险评估和缓解策略（REMS），但新一代药物已证实疗效显着，且无需此类繁琐流程，从而有助于提高患者用药可及性并简化处方通讯协定。 Axsome Therapeutics 公司的 AXS-12 等新型去甲肾上腺素再回收抑制剂的进展便是这一趋势的例证。根据 2024 年 11 月发布的新闻稿，III 期 ENCORE 试验表明，长期使用该临床实验药物治疗六个月后，平均每週猝倒发作次数减少了 77%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球嗜睡症治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗方法（伴随猝倒的嗜睡症、不伴随猝倒的嗜睡症、次发性嗜睡症）
  • 副产物（中枢神经系统兴奋剂、羟考酮钠、选择性血清素再回收抑制剂、三环抗忧郁药物、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美嗜睡症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲嗜睡症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区嗜睡症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲嗜睡症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲嗜睡症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球嗜睡症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Teva Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals, Inc.
• Harmony Biosciences
• Novartis AG
• Rhodes Pharmaceuticals LP
• Janssen Global Services, LLC
• Eli Lilly and Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Narcolepsy Therapeutics Market is projected to expand from a valuation of USD 3.42 Billion in 2025 to USD 5.09 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 6.85%. These therapeutics encompass pharmacological interventions aimed at managing a chronic neurological disorder defined by the brain's inability to regulate sleep-wake cycles, targeting symptoms like excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep. Growth in this sector is fundamentally driven by the increasing global prevalence of sleep disorders and advancements in diagnostic capabilities that facilitate earlier detection by medical professionals. Additionally, the development of mechanism-based therapies and regulatory frameworks supporting orphan drugs provide a solid foundation for industry expansion, establishing a trajectory distinct from temporary market fluctuations.

Despite these positive indicators, the market faces significant hurdles related to the complex diagnostic process, often causing substantial delays in treatment initiation. Data from the Sleep Research Society in 2023 indicates that narcolepsy affects approximately 37.7 individuals per 100,000 inhabitants. This statistic highlights the difficulty of a limited addressable patient population resulting from the condition's rarity and frequent underdiagnosis. When combined with the high expense of specialized medications, these factors create formidable barriers to rapid market scalability.

Market Driver

The market landscape for narcolepsy treatments is being fundamentally reshaped by the expansion of novel therapeutic pipelines and the approval of next-generation drugs. Pharmaceutical developers are strategically pivoting away from broad symptomatic relief toward targeted interventions that address underlying pathophysiologies, specifically focusing on orexin signaling pathways and histamine modulation. This shift is highlighted by the commercial prioritization of extended-release formulations, which significantly alleviate the dosing burden for patients; the rapid adoption of these advanced therapies confirms strong demand for treatments with better adherence profiles. For instance, Avadel Pharmaceuticals reported in their August 2024 financial results that net product revenue for LUMRYZ, their newly launched treatment, reached $41.5 million for the second quarter, demonstrating that clinical efficacy paired with dosing convenience is a major catalyst for revenue.

Simultaneously, the implementation of favorable reimbursement schemes and patient access programs acts as a critical driver by effectively converting the diagnosed population into treated patients. Recognizing the long-term economic impact of untreated sleep disorders, biopharmaceutical companies are utilizing support services to ensure sustainable medication access. According to Jazz Pharmaceuticals' report in February 2024 regarding full-year 2023 results, the average number of active patients treated with Xywav increased to approximately 12,300 in the fourth quarter. This growth in the user base directly supports substantial sector valuation, as evidenced by the $1.27 billion in annual net product sales for this franchise in 2023, underscoring the commercial viability achieved through improved patient access.

Market Challenge

The intricate diagnostic journey involved in identifying narcolepsy serves as a primary obstacle to the global therapeutics market by artificially constraining the addressable patient base. Symptoms such as excessive daytime sleepiness are often mischaracterized by general practitioners as signs of depression, insomnia, or lifestyle issues rather than a specific neurological condition. This lack of precise clinical identification creates a fragmented care pathway where patients frequently endure years of ineffective management before receiving specialized sleep care, thereby presenting pharmaceutical companies with a severely restricted market where effective therapies cannot reach unidentified or misdiagnosed individuals.

This diagnostic gap directly creates a high-risk environment for drug developers who rely on prescription volume to recoup research and development costs, effectively limiting revenue potential. The inefficiency in locating patients ensures the market size remains disproportionately small compared to the actual prevalence of the disease. According to estimates from the Narcolepsy Network in 2025, approximately 50 percent of individuals affected by this condition remain undiagnosed. This significant rate of underdiagnosis keeps the commercial market far below its true capacity, directly hampering scalability and impeding broader industry expansion.

Market Trends

A pivotal advancement in the market is the emergence of selective orexin receptor agonists, which shifts therapeutic focus from general symptomatic relief to targeting the disease's root pathophysiology. In contrast to traditional stimulants that non-selectively modulate central nervous system activity, these novel pipeline candidates are engineered to directly stimulate orexin receptors, addressing the specific neuropeptide deficiency responsible for sleep-wake instability. This mechanism-driven approach is gaining rapid clinical validation for its potential to restore natural wakefulness rather than merely masking sleepiness; for example, Takeda reported in June 2024 that their investigational oral orexin receptor 2 agonist, TAK-861, demonstrated statistically significant improvement in the Maintenance of Wakefulness Test with a p-value of less than 0.001 compared to placebo.

Concurrently, the competitive landscape is being reshaped by the development of non-scheduled therapeutics designed with lower abuse potential to overcome the restrictive access barriers linked to controlled substances. While current standard-of-care treatments often necessitate complex Risk Evaluation and Mitigation Strategies (REMS) due to their regulatory scheduling, next-generation agents are showing robust efficacy without these burdens, thereby facilitating broader patient access and simplifying prescribing protocols. This trend is illustrated by the progress of novel norepinephrine reuptake inhibitors, such as Axsome Therapeutics' AXS-12; according to a November 2024 press release, the Phase 3 ENCORE trial showed that long-term treatment with this investigational agent resulted in a 77 percent reduction in mean weekly cataplexy attacks over six months.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Jazz Pharmaceuticals, Inc.
• Harmony Biosciences
• Novartis AG
• Rhodes Pharmaceuticals L.P.
• Janssen Global Services, LLC
• Eli Lilly and Company

Report Scope

In this report, the Global Narcolepsy Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Therapeutics Market, By Treatment

• Narcolepsy with Cataplexy
• Narcolepsy Without Cataplexy
• Secondary Narcolepsy

Narcolepsy Therapeutics Market, By Product

• Central Nervous System Stimulants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Tricyclic Antidepressants
• Others

Narcolepsy Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Therapeutics Market.

Available Customizations:

Global Narcolepsy Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Narcolepsy Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Narcolepsy with Cataplexy, Narcolepsy Without Cataplexy, Secondary Narcolepsy)
  • 5.2.2. By Product (Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressants, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Narcolepsy Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Narcolepsy Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Narcolepsy Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Narcolepsy Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Product

7. Europe Narcolepsy Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Narcolepsy Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Product
  • 7.3.2. France Narcolepsy Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Narcolepsy Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Narcolepsy Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Narcolepsy Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Product

8. Asia Pacific Narcolepsy Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Narcolepsy Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Product
  • 8.3.2. India Narcolepsy Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Narcolepsy Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Narcolepsy Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Narcolepsy Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Product

9. Middle East & Africa Narcolepsy Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Narcolepsy Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Narcolepsy Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Narcolepsy Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Product

10. South America Narcolepsy Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Narcolepsy Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Narcolepsy Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Narcolepsy Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Jazz Pharmaceuticals, Inc.
• 15.3. Harmony Biosciences
• 15.4. Novartis AG
• 15.5. Rhodes Pharmaceuticals L.P.
• 15.6. Janssen Global Services, LLC
• 15.7. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer